https://www.eyegatepharma.com/ 2023-08-28T10:26+00:00 https://www.eyegatepharma.com/privacy-policy/ 2023-07-03T03:14+00:00 https://www.eyegatepharma.com/about/company-advisory-team/ 2023-07-03T03:10+00:00 https://www.eyegatepharma.com/about/ 2023-09-19T11:25+00:00 https://www.eyegatepharma.com/about/board-of-directors/ 2023-07-03T03:10+00:00 https://www.eyegatepharma.com/about/management/ 2023-07-03T03:09+00:00 https://www.eyegatepharma.com/about/scientific-advisory-board/ 2023-07-03T03:09+00:00 https://www.eyegatepharma.com/about/scientific-advisory-team/ 2023-07-03T03:09+00:00 https://www.eyegatepharma.com/events/eyegate-pharmaceuticals-aao-cocktail-party/ 2023-07-03T15:19+00:00 https://www.eyegatepharma.com/investors/analyst-info/ 2023-08-15T05:54+00:00 https://www.eyegatepharma.com/investors/corporate-governance/ 2023-07-03T03:11+00:00 https://www.eyegatepharma.com/investors/corporate-presentations/ 2023-07-03T15:18+00:00 https://www.eyegatepharma.com/investors/ir-contact/ 2023-07-03T03:14+00:00 https://www.eyegatepharma.com/investors/quarterly-results/ 2023-07-03T15:29+00:00 https://www.eyegatepharma.com/investors/sec-filings/ 2023-07-03T15:29+00:00 https://www.eyegatepharma.com/investors/stock-information/ 2023-07-03T03:12+00:00 https://www.eyegatepharma.com/ir/ 2023-07-03T03:12+00:00 https://www.eyegatepharma.com/media/eventspresentations/ 2023-07-03T03:08+00:00 https://www.eyegatepharma.com/media/press-coverage/ 2023-07-03T03:04+00:00 https://www.eyegatepharma.com/media/press-releases/ 2023-07-03T03:04+00:00 https://www.eyegatepharma.com/pipeline/ 2023-08-15T06:09+00:00 https://www.eyegatepharma.com/pipeline/egp-437/ 2024-02-12T10:12+00:00 https://www.eyegatepharma.com/pipeline/macular-edema/ 2023-07-03T03:01+00:00 https://www.eyegatepharma.com/pipeline/moxigel/ 2023-07-03T03:04+00:00 https://www.eyegatepharma.com/pipeline/non-infectious-anterior-uveitis/ 2023-07-03T03:05+00:00 https://www.eyegatepharma.com/pipeline/ocular-bandage-gel/ 2023-07-03T03:07+00:00 https://www.eyegatepharma.com/privacy-policy/ 2023-07-03T03:07+00:00 https://www.eyegatepharma.com/technology/ 2025-10-01T09:02+00:00 https://www.eyegatepharma.com/technology/benefits-of-iontophoresis/ 2023-07-03T03:07+00:00 https://www.eyegatepharma.com/technology/cmha-d-platform/ 2023-07-04T13:57+00:00 https://www.eyegatepharma.com/technology/cmha-s-platform/ 2023-07-03T03:06+00:00 https://www.eyegatepharma.com/technology/eyegate-ii-delivery-system/ 2023-07-04T14:14+00:00 https://www.eyegatepharma.com/technology/iontophoresis-delivery-system/ 2024-11-21T10:05+00:00 https://www.eyegatepharma.com/technology/pp-001/ 2023-07-03T03:00+00:00 https://www.eyegatepharma.com/contact/ 2024-02-15T11:24+00:00 https://www.eyegatepharma.com/investors/ 2023-08-15T06:09+00:00 https://www.eyegatepharma.com/drug/generic-viagra 2025-10-01T08:59+00:00 https://www.eyegatepharma.com/drug/ivermectin 2023-12-31T06:45+00:00 https://www.eyegatepharma.com/drug/generic-cialis 2023-12-31T06:33+00:00 https://www.eyegatepharma.com/news/how-to-choose-right-viagra-doses 2023-10-26T12:08+00:00 https://www.eyegatepharma.com/about/our-mission/ 2025-10-01T09:02+00:00 https://www.eyegatepharma.com/ordering-refills-delivery 2024-11-14T13:22+00:00 https://www.eyegatepharma.com/returns-and-refunds 2025-10-01T09:06+00:00 https://www.eyegatepharma.com/our-services/ 2025-10-01T09:05+00:00 https://www.eyegatepharma.com/search-and-catalog 2025-10-01T09:04+00:00 https://www.eyegatepharma.com/our-partners/ 2025-10-01T09:09+00:00 https://www.eyegatepharma.com/faq/ 2025-10-01T09:05+00:00 https://www.eyegatepharma.com/why-are-our-prices-low/ 2023-09-19T12:03+00:00 https://www.eyegatepharma.com/drug/generic-levitra 2023-12-31T06:22+00:00 https://www.eyegatepharma.com/drug/generic-priligy 2023-12-31T06:37+00:00 https://www.eyegatepharma.com/drug/flomax-tamsulosin 2023-12-31T06:06+00:00 https://www.eyegatepharma.com/drug/generic-propecia 2023-12-31T06:18+00:00 https://www.eyegatepharma.com/drug/zithromax-generic 2023-12-31T06:48+00:00 https://www.eyegatepharma.com/drug/generic-uroxatral 2023-12-31T06:30+00:00 https://www.eyegatepharma.com/drug/generic-flutamide 2023-12-31T06:25+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-positive-feedback-from-fda-regarding-ocular-bandage-gel-packaging/ 2023-10-11T07:02+00:00 https://www.eyegatepharma.com/media/sciencedirect-treatment-of-corneal-chemical-alkali-burns-with-a-crosslinked-hyaluronic-acid-film/ 2023-07-03T14:11+00:00 https://www.eyegatepharma.com/media/dr-paul-karpeckis-article-in-ocular-surface-review-ha-no-laughing-matter/ 2023-07-03T14:10+00:00 https://www.eyegatepharma.com/media/eyegate-poster-on-crosslinked-hyaluronic-acid-cmha-s-ocular-bandage-gel-based-delivery-of-small-molecules/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/media/bioworld-today-february-6-2018-eyegate-combo-candidate-foiled-by-placebo-performance-in-cataract-patients/ 2023-07-03T14:07+00:00 https://www.eyegatepharma.com/media/the-wall-street-transcript-interview-with-eyegate-ceo-stephen-from/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/media/eyegate-technology-featured-in-a-journal-of-cataract-and-refractive-surgery-article/ 2023-07-03T15:17+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-reports-third-quarter-2015-financial-results-and-provides-business-update 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-reports-full-year-2015-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-to-present-at-the-2016-aegis-capital-conference/ 2023-07-03T01:52+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-business-update/ 2023-07-03T01:52+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-business-update/ 2023-07-03T01:55+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-business-update/ 2023-07-03T01:56+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-granted-additional-180-days-to-comply-with-nasdaq-listing-rules/ 2023-07-03T01:56+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-announces-new-board-member-steven-boyd/ 2023-07-03T01:56+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharmaceuticals-announces-executive-promotions/ 2023-07-03T01:57+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-to-proceed-with-pe-pivotal-study/ 2023-07-03T01:55+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-to-present-at-the-19th-annual-rodman-and-renshaw-global-investment-conference/ 2023-07-03T01:55+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/ 2023-07-03T01:54+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-strengthens-scientific-advisory-board-with-appointments-of-daniel-s-durrie-m-d-and-randall-j-olson-m-d/ 2023-07-03T01:53+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-enrolls-first-patient-in-phase-2b-clinical-study-of-egp-437-for-cataract-surgery/ 2023-07-03T15:29+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-appoints-ryan-r-brenneman-as-chief-financial-officer/ 2023-07-03T01:54+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-appoints-dr-brenda-k-mann-as-vice-president-research-and-development/ 2023-07-03T01:54+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-awarded-448185-for-second-year-of-funding-of-phase-ii-sbir-grant-from-u-s-department-of-defense/ 2023-07-03T01:53+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-announces-interim-data-from-phase-1b-2a-clinical-trial-of-iontophoretic-egp-437-ophthalmic-solution-in-macular-edema-patients/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/uncategorized/eyegate-pharma-announces-positive-top-line-data-from-first-in-human-pilot-trial-of-ocular-bandage-gel-in-corneal-epithelial-defects 2023-07-03T01:57+00:00 https://www.eyegatepharma.com/press-release/valeant-pharmaceuticals-and-eyegate-enter-into-licensing-agreement-for-egp-437-combination-product-in-post-operative-pain-and-inflammation-in-ocular-surgery-patients/ 2023-07-03T01:59+00:00 https://www.eyegatepharma.com/press-release/some-title 2023-07-03T01:59+00:00 https://www.eyegatepharma.com/press-release/fda-confirms-a-510k-de-novo-path-for-eyegates-device-the-ocular-bandage-gel-following-pre-submission-meeting 2023-07-03T01:59+00:00 https://www.eyegatepharma.com/press-release/eyegate-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference/ 2023-07-03T01:58+00:00 https://www.eyegatepharma.com/press-release/eyegate-to-present-at-the-2018-bio-ceo-investor-conference/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-submits-investigational-device-exemption-ide-filing-for-second-pilot-study-of-ocular-bandage-gel/ 2023-10-10T04:35+00:00 https://www.eyegatepharma.com/press-release/eyegate-signs-licensing-agreement-with-valeant-pharmaceuticals-for-egp-437-combination-product-in-uveitis 2023-07-03T01:57+00:00 https://www.eyegatepharma.com/press-release/eyegate-reports-positive-data-from-third-stage-of-phase-1b2a-clinical-trial-of-egp-437-in-cataract-surgery-patients/ 2023-07-03T02:00+00:00 https://www.eyegatepharma.com/press-release/eyegate-receives-milestone-payment-from-valeant-pharmaceuticals-for-egp-437-for-post-operative-ocular-inflammation-and-pain-in-ocular-surgery-patients 2023-07-03T02:02+00:00 https://www.eyegatepharma.com/press-release/eyegate-receives-approval-from-fda-to-initiate-prk-pivotal-study/ 2023-07-03T02:02+00:00 https://www.eyegatepharma.com/press-release/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437-3/ 2023-07-03T02:01+00:00 https://www.eyegatepharma.com/press-release/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437-2/ 2023-07-03T02:01+00:00 https://www.eyegatepharma.com/press-release/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437/ 2023-07-03T15:34+00:00 https://www.eyegatepharma.com/press-release/eyegate-promotes-sarah-romano-to-chief-financial-officer/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-to-present-at-the-noble-financial-capital-markets-13th-annual-investor-conference 2023-07-03T02:00+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-to-present-at-the-noble-financial-capital-markets-12th-annual-investor-conference/ 2023-07-03T02:02+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-to-present-at-the-18th-annual-rodman-and-renshaw-global-investment-conference/ 2023-07-03T02:04+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-to-present-at-the-17th-annual-rodman-and-renshaw-global-investment-conference/ 2023-07-03T02:04+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-to-present-at-bio-ceo-investor-conference-in-new-york-city/ 2023-07-03T02:04+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-signs-technology-transfer-and-license-agreement-with-sentrx-animal-care 2023-07-03T02:03+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-business-update 2023-07-03T02:03+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-update 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-third-quarter-2016-financial-results-and-provides-business-update 2023-07-03T02:03+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-business-update/ 2023-07-03T02:02+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business-update/ 2023-07-03T02:06+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-full-year-2018-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-full-year-2017-financial-results-and-provides-business-update/ 2023-07-03T02:06+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-full-year-2016-financial-results-and-provides-business-update/ 2023-07-03T02:06+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-reports-full-year-2014-financial-results 2023-07-03T15:34+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-names-michael-b-raizman-md-consulting-chief-medical-officer-distinguished-ophthalmic-leader-to-support-ongoing-clinical-development-of-lead-product-egp-437/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-inc-prices-4100000-initial-public-offering/ 2023-07-03T02:04+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-inc-announces-closing-of-initial-public-offering-of-approximately-4100000-of-common-stock/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-completes-enrollment-in-both-prk-and-pe-pilot-studies/ 2023-07-03T02:08+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-pricing-of-10000000-public-offering-of-common-stock-and-warrants 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-participation-at-the-h-c-wainwright-20th-annual-global-investment-conference/ 2023-07-03T02:07+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-new-board-member-steven-boyd/ 2023-07-03T02:07+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-new-board-member-peter-greenleaf/ 2023-07-03T02:08+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-meeting-date-with-fda/ 2023-07-03T02:09+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-management-transition-in-support-of-strategic-transformation/ 2023-07-03T02:11+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-warrants 2023-07-03T02:11+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharmaceuticals-announces-appointment-of-brian-m-strem-ph-d-as-president-and-chief-executive-officer/ 2023-07-03T02:10+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-treats-first-patient-in-phase-1b-2a-trial-of-egp-437-in-macular-edema/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-to-present-four-posters-at-arvo-2016-annual-meeting-supporting-development-of-cmha-s 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-to-present-at-jefferies-2020-virtual-healthcare-conference/ 2023-07-03T02:09+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-to-present-at-h-c-wainwright-21st-annual-global-investment-conference/ 2023-07-03T02:09+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-to-participate-at-the-30th-annual-roth-conference/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-submits-investigational-device-exemption-amendment-for-second-pilot-study-of-ocular-bandage-gel/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-third-quarter-2020-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-third-quarter-2019-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-second-quarter-2021-financial-results-and-provides-business-update/ 2023-07-03T02:12+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-second-quarter-2020-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-second-quarter-2019-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-full-year-2020-financial-results-and-provides-business-update/ 2023-07-03T02:13+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-full-year-2019-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-first-quarter-2021-financial-results-and-provides-business-update/ 2023-07-03T02:12+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-first-quarter-2020-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reports-first-quarter-2019-financial-results-and-provides-business-update/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-regains-nasdaq-listing-compliance/ 2023-07-03T02:16+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-uspto-notice-of-allowance-for-proprietary-dexamethasone-phosphate-formulation/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-uspto-notice-of-allowance-for-next-generation-of-proprietary-iontophoretic-delivery-system/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-positive-nasdaq-listing-determination/ 2023-07-03T02:15+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-positive-guidance-from-fda-on-nda-filing-requirements-of-egp-437-for-the-treatment-of-anterior-uveitis 2023-07-04T14:14+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-approval-from-fda-to-initiate-pe-pilot-study/ 2023-07-03T02:14+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-receives-1-9-million-from-exercised-warrants/ 2023-07-03T02:18+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reaches-75-randomization-of-patients-in-pivotal-study/ 2023-07-03T02:18+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-reaches-50-randomization-of-patients-in-pivotal-study/ 2023-07-03T02:17+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-hits-primary-endpoint-in-prk-pivotal-study/ 2023-07-03T02:18+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-enrolls-first-patient-in-follow-on-pe-pilot-study/ 2023-07-03T02:17+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-enrolls-first-patient-in-confirmatory-phase-3-clinical-trial-egp-437-006-for-non-infectious-anterior-uveitis/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-confirms-path-forward-with-fda-to-develop-combination-product/ 2023-07-03T02:16+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-completes-target-enrollment-in-phase-2-proof-of-concept-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/ 2023-07-03T02:20+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-completes-randomization-in-pivotal-study/ 2023-07-03T02:19+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-completes-enrollment-in-follow-on-pe-pilot-study/ 2023-07-03T02:19+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-awarded-canadian-patent-for-proprietary-iontophoretic-formulation-and-use-of-the-formulation-for-ocular-delivery-of-dexamethasone-phosphate/ 2023-07-03T02:19+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-transformative-acquisition-of-panoptes-pharma/ 2023-07-03T02:19+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors/ 2023-07-03T02:18+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-reverse-stock-split-effective-august-30-2019/ 2023-07-03T02:20+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-randomization-of-first-25-of-patients-in-pivotal-study/ 2023-07-03T02:21+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-positive-topline-data-in-follow-on-dry-eye-pilot-study/ 2023-07-03T02:22+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-positive-results-in-second-prk-study/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-positive-results-in-punctate-epitheliopathy-study/ 2023-07-03T02:22+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-at-the-market-issuance-program/ 2023-07-03T02:22+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-announces-additional-positive-top-line-data-in-prk-pivotal-study/ 2023-07-03T02:21+00:00 https://www.eyegatepharma.com/press-release/eyegate-pharma-acquires-jade-therapeutics 2023-07-03T02:22+00:00 https://www.eyegatepharma.com/press-release/eyegate-launches-social-media-pages-to-enhance-investor-and-trade-relationships/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-issued-new-patent-for-iontophoretic-contact-lens-technology/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-files-supplement-to-investigational-device-exemption-to-commence-study-in-punctate-epitheliopathy-using-the-eyegate-ocular-bandage-gel/ 2023-07-03T02:25+00:00 https://www.eyegatepharma.com/press-release/eyegate-files-ide-with-fda-for-prk-pivotal-study/ 2023-07-03T02:25+00:00 https://www.eyegatepharma.com/press-release/eyegate-files-fda-submission-to-initiate-pe-pilot-study/ 2023-07-03T02:24+00:00 https://www.eyegatepharma.com/press-release/eyegate-enters-into-agreement-for-8-0-million-private-placement/ 2023-07-03T02:24+00:00 https://www.eyegatepharma.com/press-release/eyegate-enters-into-agreement-for-1-9-million-private-placement/ 2023-07-03T02:24+00:00 https://www.eyegatepharma.com/press-release/eyegate-confirms-path-to-de-novo-filing-with-fda/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-completes-enrollment-in-phase-2b-clinical-trial-of-egp-437-for-cataract-surgery/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-completes-enrollment-and-receives-milestone-payment-for-confirmatory-phase-3-clinical-study-of-egp-437-in-anterior-uveitis/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-awarded-new-u-s-patent-for-iontophoretic-delivery-of-corticosteroids-to-the-eye/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-appoints-mike-garanzini-as-chief-commercial-officer-to-develop-and-implement-global-launch-strategy/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-top-line-results-for-phase-3-trial-of-egp-437-in-anterior-uveitis/ 2023-07-03T02:27+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-randomization-of-first-patients-in-study-for-punctate-epitheliopathies/ 2023-07-03T02:27+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-positive-top-line-data-from-phase-1b2a-clinical-trial-of-egp-437-for-treatment-of-post-operative-inflammation-and-pain-in-cataract-surgery-patients/ 2023-07-03T02:28+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-first-patient-enrolled-in-prk-pivotal-study/ 2023-07-03T02:26+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-fda-approval-of-two-ide-submissions-for-ocular-bandage-gel/ 2023-07-03T02:27+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/ 2023-07-03T02:30+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-encouraging-interim-data-from-phase-1b2a-clinical-trial-of-egp-437-for-treatment-of-ocular-inflammation-and-pain-post-cataract-surgery/ 2023-07-03T02:30+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-completion-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/ 2023-07-03T02:29+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-completion-of-3-77-million-registered-direct-offering/ 2023-07-03T15:33+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-completion-of-11-25-million-public-offering/ 2023-07-03T02:28+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/ 2023-07-03T02:28+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-3-77-million-registered-direct-offering 2023-07-03T02:30+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-11-25-million-public-offering/ 2023-07-03T02:28+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-10-0-million-public-offering/ 2023-07-03T02:31+00:00 https://www.eyegatepharma.com/press-release/eyegate-addresses-majority-of-fdas-action-items-with-submission-of-investigational-device-exemption-amendment-for-ocular-bandage-gel/ 2023-07-03T02:31+00:00 https://www.eyegatepharma.com/press-release/eyegate-achieves-75-enrollment-in-pivotal-phase-3-clinical-trial-for-anterior-uveitis-triggering-milestone-payment 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eye-care-thought-leaders-join-eyegate-scientific-advisory-board/ 2023-07-03T15:37+00:00 https://www.eyegatepharma.com/press-release/eyegate-addresses-final-fda-action-item-with-submission-of-ide-amendment-for-ocular-bandage-gel/ 2023-07-03T02:30+00:00 https://www.eyegatepharma.com/press-release/eyegate-announces-10-75-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/ 2023-10-10T07:12+00:00